Dear [Name],

Yes, I will do so. Thank you.

Best Regards,

European Association of Euro-Pharmaceutical Companies
Rue des Deux Eglises 26 | B-1000 Bruxelles
www.eapec.org | P: +32-22414451

Dear [Name],

[Name] has asked me to reply to you. Next spring is proving to be very busy for us ([Name] especially) but I would be happy to meet with you in February. Could you send me a reminder and your final position in January and we can arrange a time for a meeting?

Best wishes,

[Name]
We will revise in more depth in January what to think of the Latvian request. Would you have time to meet in mid- or late February on the matter?

I do not see it connected to the shortages study (which I understand is more connected to the exports and analysing whether it is a root cause). The Communication is purely (today at least) on how to handle the parallel import in Member States.

Best Regards,

European Association of Euro-Pharmaceutical Companies
Rue des Deux Eglises 26 | B-1000 Bruxelles
www.eaepc.org | P: +32-22414451

From: @ec.europa.eu <@ec.europa.eu>
Sent: 12 December 2019 14:19
To: @eaepc.org>
Cc: @ec.europa.eu; @ec.europa.eu
Subject: RE: Parallel import

Dear ,
Thank you for flagging Lithuania’s remark in the EPSCO. We have not planned to update or to issue a communication on parallel trade.
For the moment, we have only planned a study on shortages of medicines in 2020. Moreover, the activities around the pharmaceutical legislation have not yet been fixed for the new Commission.

Best regards,

From: <@eaepc.org>
Sent: Thursday, December 12, 2019 11:36 AM
To: (SANTE) <@ec.europa.eu>; (SANTE) <@ec.europa.eu>
Cc: (SANTE) <@ec.europa.eu>
Subject: Parallel import

Dear ,

I noted during the EPSCO meeting on Monday, that Lithuania asked for an update of the 2003 Communication on parallel import (COM(2003)839 final).
Is this something that is subsequently being considered in the Commission? I ask as it is sort of our “mother-ship” for a somewhat harmonised approach in Member States (albeit not a lot of harmonisation have been the result) since we are not really regulated anywhere else in EU legislation. Only a note on our existence in Article 76.3 and 76.4 in Directive 2001/83 and Article 57(o) in Regulation 726/2004.

We had some experts gathered yesterday, and they agreed that case law (which is basically what the Communication sums up) has evolved since then and FMD has been introduced, that an update may make sense (we didn’t go into the details).

Looking forward to understand where you may stand on this.

Best Regards,

European Association of Euro-Pharmaceutical Companies
Rue des Deux Eglises 26 | B-1000 Bruxelles
www.eaepc.org | P: +32-22414451